Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News from CORT

3 A-Rated Biotech Stocks for Your 2024 Portfolio

Inelastic demand for healthcare products and services and the increasing government initiatives around the world are expected to boost the biotech industry. Therefore, it could be wise to buy fundamentally strong biotech stocks Entrada Therapeutics (TRDA), Corcept Therapeutics (CORT), and Alkermes (ALKS) this year. Read more.

StockNews.com

Investors Keeping a Close Eye on These 3 Biotech Stocks

Growing adoption of AI technologies by biopharmaceutical companies and growing foothold of personalized medicine are expected to drive growth in the biotech market. Therefore, it could be wise to buy fundamentally strong biotech stocks Regeneron Pharmaceuticals (REGN), Corcept Therapeutics (CORT), and Incyte (INCY). Read more.

StockNews.com

3 Biotechs with Massive Growth Potential

These three biotech stocks have massive growth opportunities on the horizon, and could add a huge boost to any portfolio. They play in some of the most in demand markets on the planet, and have track records of finding ways to introduce products into those markets to capture big profits.…

StockNews.com

From analysis to the latest developments in health,
read the most diverse news in one place.

Unlocking Biotech's Potential With 3 Stocks to Buy

The biotech industry’s growth is propelled by strong demand for medical support and interventions, favorable government initiatives, and rapid adoption of emerging technologies. Given the industry’s tailwinds, quality biotech stocks Shionogi (SGIOY), United Therapeutics (UTHR), and Corcept Therapeutics (CORT) could be ideal buys now. Read on….

StockNews.com

Which Stock Do Investors Consider a Heathier Investment: Bionano Genomics (BNGO) vs. Corcept Therapeutics (CORT)

The biotech industry is poised for long-term growth supported by government initiatives and the rising prevalence of chronic illnesses. While biotech stocks Bionano Genomics (BNGO) and Corcept Therapeutics (CORT) should benefit from the industry tailwinds, let us determine which stock could be considered a healthier investment.

StockNews.com

Time to Capitalize on These 3 Hot Biotech Stocks

The biotech industry is well-positioned for growth thanks to rising demand for quality healthcare, the prevalence of chronic diseases, and the government’s push to boost domestic biotech production and research. To that end, it could be wise to buy fundamentally strong biotech stocks Corcept Therapeutics (CORT), Ligand Pharmaceuticals (LGND), and…

StockNews.com

Are These 3 Biotech Stocks Good Buys?

Given that the biotech sector is rapidly expanding with robust demand, technology advancements, and government initiatives, fundamentally strong biotech stocks Incyte (INCY), Corcept Therapeutics (CORT), and Entrada Therapeutics (TRDA) look poised to generate significant returns. Hence, these stocks could be solid additions to your portfolio. Read on.

StockNews.com

Read news from The Economist, FT, and more,
with one subscription

Cort G300 Glam and G300 Raw review

Cor-Tek might make a colossal number of guitars for other people, but its own brand, Cort, is gaining traction with sharply priced and very well-spec’d guitars such as this new G300 duo

Guitar World

Top 3 Biotech Stocks with Breakout Potential

The biotech industry is well-positioned to witness significant growth due to technological advancements and government spending. Moreover, given the sector’s defensive nature, biotech stocks Amicus Therapeutics (FOLD), Corcept Therapeutics (CORT), and Harmony Biosciences (HRMY) might be solid buys in 2023. Read on.

StockNews.com

Cort KX700 EverTune review

“Siri, show me a modern S-style that is spec’d up for metal and has state-of-the-art hardware that keeps it in tune all of the time…”

Guitar World

2 Under-The-Radar Stocks to Buy Now Before Wall Street Catches On

With the combination of still-higher rates and widespread recessionary concerns, the stock market will likely stay under pressure for the near term. Therefore, it could be wise to buy fundamentally strong stocks Corcept Therapeutics (CORT) and Arcos Dorados (ARCO) that are flying under the radar now before Wall Street catches…

StockNews.com

2 Biotech Stocks Under $100 to Buy Now

The biotech industry flourished amid the pandemic, and lucrative federal investments are expected to drive further growth in the sector. Moreover, amid evolving variants of Coronavirus, the biotech industry is expected to remain in the limelight. Given the sound prospects of the industry, quality biotech stocks Gilead Sciences (GILD) and…

StockNews.com

3 Biotech Stocks to Accumulate During the Bear Market

2022 has been a challenging year for investors due to the combination of inflation and a slowing economy. Biotech stocks could be a place where investors can find outperformance given their low valuations and strong long-term fundamentals. Amgen (AMGN), Corcept Therapeutics (CORT), and Regneron (REGN) are 3 to consider.

StockNews.com

Growing institutional interest in community housing

Large investors see an opportunity in the $4 billion in housing supplements paid out annually, the government sees a win.

Newsroom.co.nz

Get all your
news in one place.

100’s of premium titles.
One news app.

StockNews.com

3 Biotech Stocks to Beat the Bear Market

2022 is a challenging year for the market. After battling surging inflation for the first six months, another threat is emerging with rising recession risk. Biotech stocks could be a place where investors can find outperformance given their low valuations and strong long-term fundamentals.

StockNews.com

4 Biotech Stocks to Add to Your Watchlist

The surging demand for viable drugs and vaccines, advanced therapies, and increasing investments in research and development make the biotech industry’s prospects bright. Thus, it could be wise to invest in fundamentally sound biotech stocks Amgen (AMGN), Vertex Pharmaceuticals (VRTX), BioNTech (BNTX), and Corcept Therapeutics (CORT).

Benzinga

Corcept Therapeutics's Return On Capital Employed Overview

According to Benzinga Pro, during Q4, Corcept Therapeutics (NASDAQ:CORT) earned $32.05 million, a 5.19% increase from the preceding quarter. Corcept Therapeutics also posted a total of $98.82 million in sales, a 2.8% increase since Q3.

Benzinga

Recap: Corcept Therapeutics Q4 Earnings

Corcept Therapeutics (NASDAQ:CORT) reported its Q4 earnings results on Tuesday, February 15, 2022 at 04:00 PM. Here's what investors need to know about the announcement.

Get all your
news in one place.

100’s of premium titles.
One news app.

1 2

People

Dipanjan BanchurSince

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

the European Commission

Vertex Pharmaceuticals Incorporated

63 stories

Arco

55 stories

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.